Overcoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins

Cancer Letters

Volumn 354, Issue 2, 2014, Pages 365-377

  Boeckx, Carolien ^a   Op de Beeck, Ken ^a,b   Wouters, An ^a   Deschoolmeester, Vanessa ^a   Limame, Ridha ^a   Zwaenepoel, Karen ^b   Specenier, Pol ^a,b   Pauwels, Patrick ^a,b   Vermorken, Jan B ^a,b   Peeters, Marc ^a,b   Van Camp, Guy ^a,b   Baay, Marc ^a   Lardon, Filip ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Anti EGFR therapy; Aurora kinase B; Cetuximab resistance; Dual specificity phosphatase 5 and 6; Head and neck squamous cell carcinoma; NanoPro 1000

Indexed keywords

APIGENIN; BARASERTIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PANITUMUMAB; RAS PROTEIN; 2-((3-((4-((5-(2-((3-FLUOROPHENYL)AMINO)-2-OXOETHYL)-1H-PYRAZOL-3-YL)AMINO)QUINAZOLIN-7-YL)OXY)PROPYL)(ETHYL)AMINO)ETHYL DIHYDROGEN PHOSPHATE; ANTINEOPLASTIC AGENT; AURKB PROTEIN, HUMAN; AURORA B KINASE; DUAL SPECIFICITY PHOSPHATASE; MAPK1 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ORGANOPHOSPHATE; QUINAZOLINE DERIVATIVE;

ADULT; ARTICLE; AURKB GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DUSP5 GENE; DUSP6 GENE; ENZYME PHOSPHORYLATION; FEMALE; GENE; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IC50; MALE; MICROARRAY ANALYSIS; SIGNAL TRANSDUCTION; VALIDATION STUDY; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; HEAD AND NECK NEOPLASMS; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AURORA KINASE B; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; DUAL-SPECIFICITY PHOSPHATASES; GENE EXPRESSION PROFILING; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; ORGANOPHOSPHATES; PHOSPHORYLATION; QUINAZOLINES;

EID: 84908010607     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.08.039     Document Type: Article

References (72)

1. Molinolo A.A., Amornphimoltham P., Squarize C.H., Castilho R.M., Patel V., Gutkind J.S. Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 2009, 45:324-334.
2. Mao L., Hong W.K., Papadimitrakopoulou V.A. Focus on head and neck cancer. Cancer Cell 2004, 5:311-316.
3. Graziano A., d'Aquino R., Tirino V., Desiderio V., Rossi A., Pirozzi G. The stem cell hypothesis in head and neck cancer. J. Cell. Biochem 2008, 103:408-412.
4. Moon C., Chae Y.K., Lee J. Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab. Exp. Biol. Med. (Maywood) 2010, 235:907-920.
5. Herbst R.S., Hong W.K. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Semin. Oncol 2002, 29:18-30.
6. Needle M.N. Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Semin. Oncol 2002, 29:55-60.
7. Ang K.K., Berkey B.A., Tu X., Zhang H.Z., Katz R., Hammond E.H., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002, 62:7350-7356.
8. Schneider-Merck T., Lammerts van Bueren J.J., Berger S., Rossen K., van Berkel P.H., Derer S., et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J. Immunol 2010, 184:512-520.
9. Vermorken J.B., Trigo J., Hitt R., Koralewski P., Diaz-Rubio E., Rolland F., et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J. Clin. Oncol 2007, 25:2171-2177.
10. Vermorken J.B., Mesia R., Rivera F., Remenar E., Kawecki A., Rottey S., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med 2008, 359:1116-1127.
11. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med 2006, 354:567-578.
12. Lievre A., Bachet J.B., Le Corre D., Boige V., Landi B., Emile J.F., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66:3992-3995.
13. Szabo B., Nelhubel G.A., Karpati A., Kenessey I., Jori B., Szekely C., et al. Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas. Oral Oncol 2011, 47:487-496.
14. Van Damme N., Deron P., Van Roy N., Demetter P., Bols A., Van Dorpe J., et al. Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer 2010, 10:189.
15. Boeckx C., Weyn C., Vanden Bempt I., Deschoolmeester V., Wouters A., Specenier P., et al. Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response. BMC Res. Notes 2014, 7:337.
16. Boeckx C., Baay M., Wouters A., Specenier P., Vermorken J.B., Peeters M., et al. Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance. Oncologist 2013, 18:850-864.
17. Pauwels B., Korst A.E., de Pooter C.M., Pattyn G.G., Lambrechts H.A., Baay M.F., et al. Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies. Cancer Chemother. Pharmacol 2003, 51:221-226.
18. Deschoolmeester V., Boeckx C., Baay M., Weyler J., Wuyts W., Van Marck E., et al. KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis. Br. J. Cancer 2010, 103:1627-1636.
19. de Roda Husman A.M., Walboomers J.M., van den Brule A.J., Meijer C.J., Snijders P.J. The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J. Gen. Virol 1995, 76(Pt 4):1057-1062.
20. Dunning M.J., Smith M.L., Ritchie M.E., Tavare S. beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 2007, 23:2183-2184.
21. Wettenhall J.M., Smyth G.K. limmaGUI: a graphical user interface for linear modeling of microarray data. Bioinformatics 2004, 20:3705-3706.
22. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. U.S.A. 2005, 102:15545-15550.
23. Lallemant B., Evrard A., Combescure C., Chapuis H., Chambon G., Raynal C., et al. Reference gene selection for head and neck squamous cell carcinoma gene expression studies. BMC Mol. Biol 2009, 10:78.
24. Reiter R., Gais P., Jutting U., Steuer-Vogt M.K., Pickhard A., Bink K., et al. Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin. Cancer Res 2006, 12:5136-5141.
25. Royce M.E., Xia W., Sahin A.A., Katayama H., Johnston D.A., Hortobagyi G., et al. STK15/Aurora-A expression in primary breast tumors is correlated with nuclear grade but not with prognosis. Cancer 2004, 100:12-19.
26. Atienza J.M., Yu N., Kirstein S.L., Xi B., Wang X., Xu X., et al. Dynamic and label-free cell-based assays using the real-time cell electronic sensing system. Assay Drug Dev. Technol 2006, 4:597-607.
27. Yamamoto C., Basaki Y., Kawahara A., Nakashima K., Kage M., Izumi H., et al. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res 2010, 70:8715-8725.
28. Lindsley R.C., Gill J.G., Murphy T.L., Langer E.M., Cai M., Mashayekhi M., et al. Mesp1 coordinately regulates cardiovascular fate restriction and epithelial-mesenchymal transition in differentiating ESCs. Cell Stem Cell 2008, 3:55-68.
29. Deraz E.M., Kudo Y., Yoshida M., Obayashi M., Tsunematsu T., Tani H., et al. MMP-10/stromelysin-2 promotes invasion of head and neck cancer. PLoS ONE 2011, 6:e25438.
30. Qin L., Chen X., Wu Y., Feng Z., He T., Wang L., et al. Steroid receptor coactivator-1 upregulates integrin alpha(5) expression to promote breast cancer cell adhesion and migration. Cancer Res 2011, 71:1742-1751.
31. Sarrio D., Franklin C.K., Mackay A., Reis-Filho J.S., Isacke C.M. Epithelial and mesenchymal subpopulations within normal basal breast cell lines exhibit distinct stem cell/progenitor properties. Stem Cells 2012, 30:292-303.
32. Guix M., Faber A.C., Wang S.E., Olivares M.G., Song Y., Qu S., et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest 2008, 118:2609-2619.
33. Cortot A.B., Repellin C.E., Shimamura T., Capelletti M., Zejnullahu K., Ercan D., et al. Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res 2013, 73:834-843.
34. Bermudez O., Pages G., Gimond C. The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. Am. J. Physiol. Cell Physiol 2010, 299:C189-C202.
35. Kucharska A., Rushworth L.K., Staples C., Morrice N.A., Keyse S.M. Regulation of the inducible nuclear dual-specificity phosphatase DUSP5 by ERK MAPK. Cell. Signal 2009, 21:1794-1805.
36. Furukawa T., Tanji E., Kuboki Y., Hatori T., Yamamoto M., Shimizu K., et al. Targeting of MAPK-associated molecules identifies SON as a prime target to attenuate the proliferation and tumorigenicity of pancreatic cancer cells. Mol. Cancer 2012, 11:88.
37. Keyse S.M. Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. Curr. Opin. Cell Biol 2000, 12:186-192.
38. Kelly K.R., Ecsedy J., Mahalingam D., Nawrocki S.T., Padmanabhan S., Giles F.J., et al. Targeting aurora kinases in cancer treatment. Curr. Drug Targets 2011, 12:2067-2078.
39. Okudela K., Yazawa T., Woo T., Sakaeda M., Ishii J., Mitsui H., et al. Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis. Am. J. Pathol 2009, 175:867-881.
40. Bonet C., Giuliano S., Ohanna M., Bille K., Allegra M., Lacour J.P., et al. Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells. J. Biol. Chem 2012, 287:29887-29898.
41. Furukawa T., Kanai N., Shiwaku H.O., Soga N., Uehara A., Horii A. AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer. Oncogene 2006, 25:4831-4839.
42. Sok J.C., Coppelli F.M., Thomas S.M., Lango M.N., Xi S., Hunt J.L., et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin. Cancer Res 2006, 12:5064-5073.
43. Lievre A., Bachet J.B., Boige V., Cayre A., Le Corre D., Buc E., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol 2008, 26:374-379.
44. Amado R.G., Wolf M., Peeters M., Van Cutsem E., Siena S., Freeman D.J., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol 2008, 26:1626-1634.
45. Patel D., Lahiji A., Patel S., Franklin M., Jimenez X., Hicklin D.J., et al. Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface. Anticancer Res 2007, 27:3355-3366.
46. Kondo N., Tsukuda M., Taguchi T., Nakazaki K., Sakakibara A., Takahashi H., et al. Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities. Cancer Sci 2011, 102(9):1717-1723. 10.1111/j.1349-7006.2011.01999.x.
47. Nestor M. Effect of cetuximab treatment in squamous cell carcinomas. Tumour Biol 2010, 31:141-147.
48. Murray S., Bobos M., Angouridakis N., Nikolaou A., Linardou H., Razis E., et al. Screening for EGFR mutations in patients with head and neck cancer treated with gefitinib on a compassionate-use program: a Hellenic Cooperative Oncology Group Study. J. Oncol 2010, (2010). 709678.
49. Bruckman K.C., Schonleben F., Qiu W., Woo V.L., Su G.H. Mutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod 2010, 110:632-637.
50. Ercan D., Xu C., Yanagita M., Monast C.S., Pratilas C.A., Montero J., et al. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov 2012, 2(10):934-947. 10.1158/2159-8290.CD-12-0103.
51. Huang C.Y., Tan T.H. DUSPs, to MAP kinases and beyond. Cell Biosci 2012, 2:24.
52. O-charoenrat P., Rhys-Evans P.H., Modjtahedi H., Eccles S.A. The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma. Oral Oncol 2002, 38:627-640.
53. Oliveras-Ferraros C., Vazquez-Martin A., Queralt B., Adrados M., Ortiz R., Cufi S., et al. Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux(R)) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models. Int. J. Oncol 2011, 39:1455-1479.
54. Gazel A., Nijhawan R.I., Walsh R., Blumenberg M. Transcriptional profiling defines the roles of ERK and p38 kinases in epidermal keratinocytes. J. Cell. Physiol 2008, 215:292-308.
55. Haddad Y., Choi W., McConkey D.J. Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines. Clin. Cancer Res 2009, 15:532-542.
56. Skvortsova I., Skvortsov S., Raju U., Stasyk T., Riesterer O., Schottdorf E.M., et al. Epithelial-to-mesenchymal transition and c-myc expression are the determinants of cetuximab-induced enhancement of squamous cell carcinoma radioresponse. Radiother. Oncol 2010, 96:108-115.
57. Wong V.C., Chen H., Ko J.M., Chan K.W., Chan Y.P., Law S., et al. Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype. Int. J. Cancer 2012, 130:83-95.
58. Furukawa T., Horii A. Molecular pathology of pancreatic cancer: in quest of tumor suppressor genes. Pancreas 2004, 28:253-256.
59. Xu S., Furukawa T., Kanai N., Sunamura M., Horii A. Abrogation of DUSP6 by hypermethylation in human pancreatic cancer. J. Hum. Genet 2005, 50:159-167.
60. Shin S.H., Park S.Y., Kang G.H. Down-regulation of dual-specificity phosphatase 5 in gastric cancer by promoter CpG island hypermethylation and its potential role in carcinogenesis. Am. J. Pathol 2013, 182:1275-1285.
61. Masuelli L., Marzocchella L., Quaranta A., Palumbo C., Pompa G., Izzi V., et al. Apigenin induces apoptosis and impairs head and neck carcinomas EGFR/ErbB2 signaling. Front. Biosci. (Landmark Ed.) 2011, 16:1060-1068.
62. Chan L.P., Chou T.H., Ding H.Y., Chen P.R., Chiang F.Y., Kuo P.L., et al. Apigenin induces apoptosis via tumor necrosis factor receptor- and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin. Biochim. Biophys. Acta 2012, 1820:1081-1091.
63. Fey D., Croucher D.R., Kolch W., Kholodenko B.N. Crosstalk and signaling switches in mitogen-activated protein kinase cascades. Front. Physiol 2012, 3:355.
64. Wang L., Liu T., Nishioka M., Aguirre R.L., Win S.S., Okada N. Activation of ERK1/2 and cyclin D1 expression in oral tongue squamous cell carcinomas: relationship between clinicopathological appearances and cell proliferation. Oral Oncol 2006, 42:625-631.
65. McLaughlin J., Markovtsov V., Li H., Wong S., Gelman M., Zhu Y., et al. Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J. Cancer Res. Clin. Oncol 2010, 136:99-113.
66. Lens S.M., Voest E.E., Medema R.H. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat. Rev. Cancer 2010, 10:825-841.
67. Mehra R., Serebriiskii I.G., Burtness B., Astsaturov I., Golemis E.A. Aurora kinases in head and neck cancer. Lancet Oncol 2013, 14:e425-e435.
68. Li F., Yang J., Ramnath N., Javle M.M., Tan D. Nuclear or cytoplasmic expression of survivin: what is the significance?. Int. J. Cancer 2005, 114:509-512.
69. Schwartz G.K., Carvajal R.D., Midgley R., Rodig S.J., Stockman P.K., Ataman O., et al. Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. Invest. New Drugs 2013, 31:370-380.
70. Sebolt-Leopold J.S., Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 2004, 4:937-947.
71. Hoellein A., Pickhard A., von Keitz F., Schoeffmann S., Piontek G., Rudelius M., et al. Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck. Oncotarget 2011, 2:599-609.
72. Dar A.A., Goff L.W., Majid S., Berlin J., El-Rifai W. Aurora kinase inhibitors-rising stars in cancer therapeutics?. Mol. Cancer Ther 2010, 9:268-278.